Last updated: March 11, 2026
What is NDC 67457-0153?
NDC 67457-0153 refers to Elzonris (tagraxofusp), a biologic agent approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Approved by the FDA in December 2018, Elzonris is a CD123-directed cytotoxin designed to target BPDCN, a rare and aggressive hematologic malignancy.
Market Landscape
Indication and Patient Population
BPDCN remains a rare disease with limited treatment options. The estimated prevalence of BPDCN is approximately 0.1 cases per million population annually in the U.S. [1]. This translates to a small patient base, primarily impacting older adults, with limited curative options.
Approved Indications
- Adult BPDCN
- Underserved in other hematologic malignancies
Competitive Landscape
There are no direct FDA-approved alternatives for BPDCN. Off-label treatments include chemotherapies and hematopoietic stem cell transplants. However, approved targeted immunotherapies like Elzonris dominate the market for this indication.
Market Dynamics
- Growing awareness among hematologists
- Enrollment in clinical trials for related indications
- Potential expansion into other CD123-positive hematologic diseases (e.g., acute myeloid leukemia, AML)
Key Market Drivers
- FDA approval and subsequent label expansion
- Limited current treatment options for BPDCN
- High unmet medical need
Barriers
- Small patient population limits overall market size
- High treatment cost
- FDA label restrictions to BPDCN only
Regional Analysis
- U.S. market: Primary revenue generator due to FDA approval
- Europe: Pending approval, with launch latency
- Other regions: Due to small patient population and access barriers, potential sales are limited
Pricing Overview
Current Price Point
As of 2023, the typical wholesale acquisition cost (WAC) for Elzonris is approximately $25,000 per 20 microgram vial. Dosing varies based on patient weight, with an average dose of 40 micrograms/kg administered on days 1, 3, and 5 of the initial cycle, repeating every 21 days until disease progression or unacceptable toxicity.
Cost Breakdown
- Average patient weight: 70 kg
- Typical dose per cycle: 70 kg x 40 µg/kg = 2,800 µg
- Vial size: 20 µg
- Vials per dose: 140 (at $25,000 per vial)
- Total per cycle: 140 vials x $25,000 = $3.5 million
Note: Current treatment protocols involve multiple cycles, inflating total treatment costs.
Price Trends and Projections
| Year |
Estimated WAC per vial |
Estimated treatment cycle cost |
Market size (patients) |
Total potential annual sales |
| 2023 |
$25,000 |
$3.5 million (per cycle per patient) |
100-150 |
$350 million – $525 million |
| 2024 |
Maintains or slight increase |
Based on continued demand |
Slight growth expected |
Remains within $350 million – $600 million |
| 2025+ |
Price stabilization possible |
Potential reductions with biosimilars or generics |
Limited patient pool |
Limited market expansion |
Price Sensitivity Factors
- Payer negotiations may decrease net prices for insurers.
- Price competition unlikely in the near-term due to lack of direct alternatives.
- Biosimilar development possible after patent expiry, which could reduce prices by 20-40%.
Patent and Exclusivity
- Patent protection until at least 2030
- Orphan drug designation provides seven years of market exclusivity, potentially extending longer based on additional regulatory data [2].
Revenue Outlook
Given the rarity of BPDCN, annual sales are projected within the range of $350 million to $600 million in the U.S. market, assuming steady market penetration. Expansion into other indications or off-label use could increase revenues marginally.
Conclusion
Elzonris (NDC 67457-0153) addresses an unmet need in a rare disease. Pricing remains high, reflective of small patient populations and limited competition. While the current market is modest compared to blockbuster hematology drugs, steady demand persists due to lack of alternatives. Price projections suggest stability in the near-term, with potential reductions if biosimilars enter the market post-patent expiration.
Key Takeaways
- BPDCN’s small patient population constrains total market size.
- Current WAC pricing is approximately $25,000 per vial, translating to treatment costs upward of $3.5 million per patient cycle.
- Estimated annual market size: $350–600 million.
- Patent protection and orphan drug status ensure market exclusivity through at least 2030.
- Biosimilar entry could reduce prices by 20-40% in the long term.
FAQs
1. What factors influence the pricing of Elzonris?
Pricing is influenced by disease rarity, manufacturing costs, clinical value, payer negotiations, and market exclusivity.
2. Are there any potential price reductions anticipated?
Yes, biosimilar development post-patent expiry may introduce competition, reducing prices by 20-40%.
3. How does Elzonris compare to similar therapies for hematologic malignancies?
It is priced higher due to indication rarity and targeted mechanism; similar biologics vary widely in cost based on disease and treatment complexity.
4. What are the regulatory barriers to expanding Elzonris’s label?
Additional clinical trials are required to support approval for other CD123-positive diseases, which can delay market expansion.
5. What is the outlook for biosimilar entry?
Biosimilars for biologics like Elzonris are likely post-2030, depending on patent challenges and market dynamics.
References
[1] National Cancer Institute. (2022). Rare Hematologic Malignancies. https://seer.cancer.gov
[2] U.S. Food and Drug Administration. (2019). Orphan Drug Designation Facts. https://www.fda.gov
[3] IQVIA. (2023). Biopharmaceutical Pricing and Market Trends.
